These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

443 related items for PubMed ID: 17097109

  • 1. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment.
    Stefani A, Martorana A, Bernardini S, Panella M, Mercati F, Orlacchio A, Pierantozzi M.
    J Neurol Sci; 2006 Dec 21; 251(1-2):124-8. PubMed ID: 17097109
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease.
    Smach MA, Charfeddine B, Ben Othman L, Lammouchi T, Dridi H, Nafati S, Ltaief A, Bennamou S, Limem K.
    Eur Neurol; 2009 Dec 21; 62(6):349-55. PubMed ID: 19786779
    [Abstract] [Full Text] [Related]

  • 3. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
    Maccioni RB, Lavados M, Guillón M, Mujica C, Bosch R, Farías G, Fuentes P.
    Neurobiol Aging; 2006 Feb 21; 27(2):237-44. PubMed ID: 16399209
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
    Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Möller HJ, Blennow K, Buerger K.
    Mol Psychiatry; 2004 Jul 21; 9(7):705-10. PubMed ID: 14699432
    [Abstract] [Full Text] [Related]

  • 6. Abeta1-42 Detection in CSF of Alzheimer's disease is influenced by temperature: indication of reversible Abeta1-42 aggregation?
    Sancesario GM, Esposito Z, Nuccetelli M, Bernardini S, Sorge R, Martorana A, Federici G, Bernardi G, Sancesario G.
    Exp Neurol; 2010 Jun 21; 223(2):371-6. PubMed ID: 19664624
    [Abstract] [Full Text] [Related]

  • 7. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease.
    Chiasserini D, Parnetti L, Andreasson U, Zetterberg H, Giannandrea D, Calabresi P, Blennow K.
    J Alzheimers Dis; 2010 Jun 21; 22(4):1281-8. PubMed ID: 20930282
    [Abstract] [Full Text] [Related]

  • 8. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM.
    Biol Psychiatry; 2004 Nov 01; 56(9):670-6. PubMed ID: 15522251
    [Abstract] [Full Text] [Related]

  • 9. The diagnostic value of tau protein, beta-amyloid (1-42) and their ratio for the discrimination of alcohol-related cognitive disorders from Alzheimer's disease in the early stages.
    Kapaki E, Liappas I, Paraskevas GP, Theotoka I, Rabavilas A.
    Int J Geriatr Psychiatry; 2005 Aug 01; 20(8):722-9. PubMed ID: 16035118
    [Abstract] [Full Text] [Related]

  • 10. Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design.
    van Rossum IA, Vos S, Handels R, Visser PJ.
    J Alzheimers Dis; 2010 Aug 01; 20(3):881-91. PubMed ID: 20413876
    [Abstract] [Full Text] [Related]

  • 11. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
    Ibach B, Binder H, Dragon M, Poljansky S, Haen E, Schmitz E, Koch H, Putzhammer A, Kluenemann H, Wieland W, Hajak G.
    Neurobiol Aging; 2006 Sep 01; 27(9):1202-11. PubMed ID: 16085339
    [Abstract] [Full Text] [Related]

  • 12. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.
    Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H, Sasaki H, Abe K, Iwatsubo T, Kosaka T, Watanabe M, Tomidokoro Y, Shizuka M, Mizushima K, Nakamura T, Igeta Y, Ikeda Y, Amari M, Kawarabayashi T, Ishiguro K, Harigaya Y, Wakabayashi K, Okamoto K, Hirai S, Shoji M.
    Ann Neurol; 1998 Jul 01; 44(1):17-26. PubMed ID: 9667589
    [Abstract] [Full Text] [Related]

  • 13. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.
    Lewczuk P, Kornhuber J, Vanderstichele H, Vanmechelen E, Esselmann H, Bibl M, Wolf S, Otto M, Reulbach U, Kölsch H, Jessen F, Schröder J, Schönknecht P, Hampel H, Peters O, Weimer E, Perneczky R, Jahn H, Luckhaus C, Lamla U, Supprian T, Maler JM, Wiltfang J.
    Neurobiol Aging; 2008 Jun 01; 29(6):812-8. PubMed ID: 17239996
    [Abstract] [Full Text] [Related]

  • 14. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L, Udompunthuruk S.
    J Med Assoc Thai; 2011 Feb 01; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [Abstract] [Full Text] [Related]

  • 15. Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers.
    Parnetti L, Lanari A, Silvestrelli G, Saggese E, Reboldi P.
    Mech Ageing Dev; 2006 Feb 01; 127(2):129-32. PubMed ID: 16274728
    [Abstract] [Full Text] [Related]

  • 16. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology.
    Mulder SD, van der Flier WM, Verheijen JH, Mulder C, Scheltens P, Blankenstein MA, Hack CE, Veerhuis R.
    J Alzheimers Dis; 2010 Feb 01; 20(1):253-60. PubMed ID: 20164582
    [Abstract] [Full Text] [Related]

  • 17. Correlation between cognitive impairment and CSF biomarkers in amnesic MCI, non-amnesic MCI, and Alzheimer's disease.
    Haldenwanger A, Eling P, Kastrup A, Hildebrandt H.
    J Alzheimers Dis; 2010 Feb 01; 22(3):971-80. PubMed ID: 20858947
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.
    Hansson O, Buchhave P, Zetterberg H, Blennow K, Minthon L, Warkentin S.
    Neurobiol Aging; 2009 Feb 01; 30(2):165-73. PubMed ID: 17646035
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.